# Ambev S.A. American (ABEV) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Consumer Defensive / Beverages. Price $3.02, market value $46.6 billion.

## Valuation
- **P/E (trailing): 15.1×** (5-yr avg 2.5×, 3-yr avg 2.4×). Ambev S.A. American trades at 15.1× trailing earnings, well above its own five-year average of 2.5×: investors are paying up relative to the company's past. The Consumer Defensive median in the September 2026 study was 20.1×. Forward P/E is 14.1×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.61**. A PEG of 1.61 is in the range usually read as fairly priced for its growth.
- **Price / sales: 2.7×**. Each dollar of revenue is priced at 2.7×.
- **Price / book: 2.7×**. The shares trade at 2.7× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 7.5×**. Enterprise value is 7.5× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 10.1%** (5-yr avg 50.6%). Free cash flow equals 10.1% of the market value, below its five-year average of 50.6%, so the shares are pricier on cash than usual. Above 5% is generally attractive.
- **Earnings yield: 6.6%**. The inverse of the P/E: 6.6% of the price is earned each year.

## Profitability
- **Gross margin: 51.9%**. Ambev S.A. American keeps 51.9% of revenue after the direct cost of what it sells.
- **Operating margin: 26.4%**. 26.4% of revenue is left after running the business, an exceptional level.
- **Net margin: 18.1%**. 18.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 18.0%**. 18.0% on shareholders' equity is solid.
- **Return on invested capital: 26.4%**. Return on all capital, debt included, is 26.4%: comfortably above what that capital costs.
- **Return on assets: 11.2%**. Each dollar of assets produces 11.2% of profit.

## Growth
- **Revenue growth (1 yr): -1.4%** (3-yr 3.4%/yr, 5-yr 8.6%/yr). Revenue fell 1.4% over the last year, against 8.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 8.8%** (3-yr 2.8%/yr, 5-yr 6.6%/yr). Earnings per share rose 8.8%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 12.1%/yr**. Free cash flow has compounded at 12.1% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.03**. Debt is 0.03 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Ambev S.A. American holds more cash than debt.
- **Interest coverage: 8.6×**. Operating profit covers interest 8.6× over, a safe margin.
- **Altman Z-score: 2.49**. A Z-score of 2.49 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 5.28%** ($0.16 per share, trailing). Ambev S.A. American yields 5.28%, an income-level yield.
- **Consecutive years of increases: 1**. 1 straight year of increases.
- **Dividend growth (5 yr): 14.0%/yr** (1-yr 41.0%). The dividend has compounded at 14.0% a year over five years, doubling roughly every 5 years at that pace.

## Analyst view
- **Analyst consensus: hold** (10 analysts). 10 analysts cover Ambev S.A. American; the consensus is hold, with an average price target of $3.34 (+11% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 38.3%** (YTD 22.6%, 3-mo -2.9%). The shares are up 38.3% over twelve months including dividends.
- **From 52-week high: -12.5%** (43.8% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 0.54** (volatility 32%). Beta of 0.54 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ABEV · Page: https://foliofundamentals.com/stocks/abev

Not investment advice.